Abstract: A cable connector assembly includes a module retainer and a set of two or more cable insert modules sized and shaped for removable retention within two or more module slots of the module retainer. A cable insert module of the set of two or more cable insert modules includes a cable insertion recess sized and shaped for insertion of a cable wire of a cable, a connectivity interface on an opposing face of the cable insert module, and a transmission path between the cable insertion recess and the connectivity interface.

Abstract: Systems and methods for implementing an application programming interface (API) that controls operations of a machine learning tuning service for tuning a machine learning model for improved accuracy and computational performance includes an API that is in control communication the tuning service that: executes a first API call function that includes an optimization work request that sets tuning parameters for tuning hyperparameters of a machine learning model; and initializes an operation of distinct tuning worker instances of the service that each execute distinct tuning tasks for tuning the hyperparameters; executes a second API call function that identifies raw values for the hyperparameters; and generates suggestions comprising proposed hyperparameter values selected from the plurality of raw values for each of the hyperparameters; and executes a third API call function that returns performance metrics relating to a real-world performance of the subscriber machine learning model executed with the propose

Abstract: A recline lockout device is disclosed. The device includes one or more modular lockout assemblies including a housing, one or more levers, and one or more shafts. The device may include one or more lockout cables coupled to actuator assemblies of the aircraft seats and a lever. Each actuator assembly may be configured to position the aircraft seats between an upright and reclined position. The device may include one or more lockout control mechanisms configured to cause the one or more lockout cables to translate. Upon translating, the first lever or the second lever may be configured to translate to cause the first lever to disengage from the second lever. Upon disengaging the first lever from the second lever, the first recline lever may be configured to disengage from the second recline cable to prevent the actuator assemblies from actuating between the upright and reclined position.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for optimizing a process of manufacturing a product. In one aspect, the method comprises repeatedly performing the following: i) selecting a configuration of input settings for manufacturing a product, based on a causal model that measures causal relationships between input settings and a measure of a quality of the product; ii) determining the measure of the quality of the product manufactured using the configuration of input settings; and iii) adjusting, based on the measure of the quality of the product manufactured using the configuration of input settings, the causal model.

Abstract: An infant carrier assembly may be removably securable to a car seat. The infant carrier assembly may include an adapter and an infant carrier. The adapter is removably securable to the car seat. The infant carrier is removably securable to the car seat by engagement with the adapter. A car seat assembly may include a car seat and the infant carrier assembly.

Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.

Abstract: The present invention relates to a compound according to formula (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g., dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

Abstract: The present invention relates to a compound according to formula (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g., dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.

Abstract: Methods and systems for treating a spinal joint with a facet joint replacement. The prosthesis can include a first component having a first articulating surface and a second component having a second articulating surface. The first component is attached to a superior articulating facet and the second component is attached to an inferior articulating facet. The first articulating surface and the second articulating surface articulate with each other and allow for multiple degrees of movement of the facet joint without fusing the joint.

Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.

Abstract: Methods for producing graphene oxide products are disclosed. In one embodiment, a method of producing a graphene oxide product includes contacting a carbon-containing feedstock with an oxidizing composition comprising aqueous nitric acid, wherein the concentration of nitric acid is 50 to 63 wt %, to from a reactant slurry, in response to the contacting step, oxidizing the carbon-containing feedstock of the reactant slurry to form a graphite oxide slurry; and processing the graphite oxide slurry into a graphene oxide product.

Abstract: Methods and systems for treating a spinal joint with a facet joint replacement. The prosthesis can include a first component having a first articulating surface and a second component having a second articulating surface. The first component is attached to a superior articulating facet and the second component is attached to an inferior articulating facet. The first articulating surface and the second articulating surface articulate with each other and allow for multiple degrees of movement of the facet joint without fusing the joint.

Abstract: Methods and compositions for inhibiting complement are described.

Abstract: A sucker rod transfer assembly for handling a sucker rod prior to the sucker rod being installed for use in a well. The transfer assembly includes an elongated body having a cavity that receives an end of the sucker rod. A slot is formed in an end wall of the body, and an opening extends lengthwise along the body that exposes the cavity. The sucker rod is engaged with the transfer assembly by inserting a tip and shoulder of the sucker rod laterally into the opening while sliding a portion of the sucker rod below the shoulder into the slot. The sucker rod is axially supported in the transfer assembly by interfering contact between the shoulder and edges of the slot. A spring selectively biases safety rings around the sucker rod end to retain the sucker rod end in the cavity.

Abstract: A chitosan based coating system. The coating system includes a carrier agent and a chitosan based agent preservative. The carrier agent may be a cleaning agent, a polishing agent, and/or a finishing agent. The chitosan based agent may be a chitosan acetate and salts thereof, chitosan citrate acetate and salts thereof, or combinations thereof. The coating system may include 0.01-5 weight percent chitosan based agent. The chitosan based agent functions as a preservative to increase both the shelf-life and use-life of the coating system as well as functions as a chelating agent to reduce soap scum.

Abstract: Examples of employee concierge are provided. In an example, an issue may be determined for an employee. The issue may be determined based on a query shared by the employee or upon occurrence of an unusual event. The unusual event may be indicative of a deviation in behaviour and routine of the employee. A session may be initiated and the issue may be parsed to determine a context. A bot may be selected from multiple bots for the issue where each bot includes information relating to a solution to address the issue. Data associated with the issue may be collected from a central database and other bots. The data may then be analyzed to determine a solution. The solution comprises a response to the query and a suggestion to mitigate the unusual event.